参附注射液对乳腺癌术后化疗患者生存质量及其免疫功能的影响研究

doi:10.12092/j.issn.1009-2501.2018.10.012

摘要/Abstract

摘要：

目的: 研究参附注射液对乳腺癌术后化疗患者生存质量及免疫功能的影响。方法: 选择2016年12月至2017年12月在本院化疗的150例乳腺癌患者为研究对象，按照随机数表法均分为对照组和研究组。对照组给予常规化疗方案，研究组在对照组化疗的基础上联合参附注射液治疗。化疗6个疗程后，比较两组患者临床疗效，分析两组患者化疗前后T细胞亚群、自然杀伤细胞（NK细胞）水平和免疫球蛋白水平，比较两组化疗后的生存质量情况，观察不良反应发生情况。结果: 研究组临床治疗总有效率为96.00%，明显高于对照组的86.67%（P<0.05）。化疗前，两组患者的CD3+、CD4+、CD8+、CD4+/CD8+和NK细胞水平比较差异无统计学意义（P>0.05）。化疗后，两组患者的CD3+、CD4+、CD4+/CD8+和NK细胞水平均升高，研究组高于对照组；CD8+水平均下降，研究组低于对照组，两组比较差异有统计学意义（P<0.05）。化疗后，两组患者的lgG、lgA和lgM水平均下降，且研究组均明显低于对照组（P<0.05）。化疗后，研究组患者功能子量表中的躯体功能得分明显高于对照组，症状子量表中的疲劳、恶心/呕吐和疼痛得分明显低于对照组（P<0.05）。研究组总不良反应率为4.00%，明显低于对照组的14.67%，两组比较差异有统计学意义（P<0.05）。结论: 参附注射液能有效提高乳腺癌术后化疗患者免疫功能，改善患者术后生存质量，临床疗效显著，临床应用价值高。

关键词: 参附注射液, 乳腺癌, 化疗, 生存质量, 免疫功能

Abstract:

AIM: To study the effect of Shenfu injection on the quality of life and immune function in patients with breast cancer after chemotherapy. METHODS: A total of 150 patients with breast cancer who received chemotherapy in our hospital from Dec.2016 to Dec.2017 were selected and randomly divided into the study group and the control group according to the random number table method. The control group was given conventional chemotherapy; the study group received extra Shenfu injection treatment on the basis of the control group. After 6 courses of chemotherapy, the clinical efficacy of the two groups was compared. The T cell subgroup, NK cell level, immunoglobulin level and the quality of life of the two groups were analyzed before and after chemotherapy and the occurrence of adverse reactions was observed. RESULTS: The total effective rate of the study group was 96%, which was significantly higher than that of the control group (86.67%) (P<0.05). Before chemotherapy, there was no significant difference in the levels of CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells between the two groups (P>0.05). After chemotherapy, the level of CD3+, CD4+, CD4+/CD8+ and NK cells in the two groups increased, and the increase of the study group was higher than that of the control group. The level of CD8+ decreased and the decrease of the study group was lower than the control group. The two groups were significantly different (P<0.05). After chemotherapy, the lgG, lgA and lgM level of the two groups decreased, and the study group decreased more than the control group (P<0.05). After chemotherapy, the score of somatic function in the functional subscale of the study group was significantly higher than that of the control group. The scores of fatigue, nausea, vomiting and pain in the symptom subscale were significantly lower than those of the control group (P<0.05). The total adverse reaction rate in the study group was 4%, which was significantly lower than that in the control group (14.67%). There was a significant difference between the two groups (P<0.05). CONCLUSION: Shenfu injection can effectively improve the immune function of patients with breast cancer after chemotherapy, and improve the quality of life after operation. The clinical effect is remarkable and worthy of clinical application.

Key words: Shenfu injection, breast cancer, chemotherapy, quality of life, immune function

中图分类号:

R749

陈舟，黄和，陈其余. 参附注射液对乳腺癌术后化疗患者生存质量及其免疫功能的影响研究[J]. 中国临床药理学与治疗学, 2018, 23(10): 1159-1164.

CHEN Zhou, HUANG He, CHEN Qiyu. Effects of Shenfu injection on the quality of life and immune function on patients with breast cancer after chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1159-1164.

参考文献

［1］刘丽娜, 邱阚, 种宝贵, 等. 参附注射液治疗乳腺癌术后化疗致白细胞减少的临床疗效及安全性评价［J］. 中国临床药理学杂志, 2015, 31(24): 2384-2386.
［2］王海燕, 权毅, 罗杰. 参附注射液对于乳腺癌化疗患者的骨髓抑制及消化道症状的临床效果观察与分析［J］. 辽宁中医杂志, 2017, 44(2): 315-317.
［3］孙丽丽, 黄磊, 徐倩, 等. 乳腺癌术后化疗患者生命质量现状及影响因素的研究［J］. 现代预防医学, 2016, 43(21): 4024-4028.
［4］李东泽, 崔艺蕾, 汪莎莎, 等. 乳腺癌患者术后化疗期情绪障碍与健康相关生活质量研究［J］. 中华肿瘤防治杂志, 2016, 23(15): 979-982.
［5］张恒伟, 李军涛, 郭旭辉, 等. 乳腺癌新辅助化疗患者病理完全缓解的影响因素及生存分析［J］. 中国肿瘤临床, 2016, 43(18): 820-824.
［6］李小雷, 王晓琦, 屈海鸥. 参芪扶正注射液联合化疗方案对乳腺癌患者的临床疗效［J］. 中国临床药理学杂志, 2015, 31(4): 267-269.
［7］阮立为, 邓甬川. 消癌平对乳腺癌新辅助化疗疗效的增强作用及其机制探讨［J］. 中国中药杂志, 2015, 40(4): 749-752.
［8］Brasómaristany F, Filosto S, Catchpole S, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer［J］. Nat Med, 2016, 22(11): 1303.
［9］曹志宇, 何建苗, 杨波, 等. 局部晚期乳腺癌新辅助化疗联合保乳手术的临床疗效观察:附81例报告［J］. 解放军医学杂志, 2015, 40(6): 488-491.
［10］秦春华, 李凤霞. 小柴胡汤辅助化疗治疗晚期乳腺癌的近期疗效观察及其对肿瘤标志物的影响［J］. 中国医院药学杂志, 2015, 35(15): 1420-1421+1438.
［11］Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast- conserving therapy ［J］. Annal Surgical Oncol, 2016, 23(3): 749-756.
［12］崔宇, 姚嫱, 刘利萍, 等. 益气生血方对乳腺癌患者辅助化疗后骨髓抑制的影响［J］. 中医杂志, 2014, 55(8): 684-686.
［13］周立艳, 史业辉, 汪旭, 等. 三阴性乳腺癌新辅助化疗疗效及预后分析［J］. 肿瘤, 2014, 34(5): 454-457+463.
［14］Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy ［J］. J Clin Oncol, 2016, 25(28): 4396-4404.
［15］倪志强, 方艳秋, 刘多, 等. DC-CIK联合化疗对乳腺癌患者免疫功能、无进展生存期及生活质量的影响［J］. 中国妇幼保健, 2013, 28(31): 5134-5137.
［16］Farthmann J, Hanjalic-Beck A, Veit J, et al. The impact of chemotherapy for breast cancer on sexual function and health-related quality of life ［J］. Support Care Cancer, 2016, 24(6): 1-7.
［17］刘志勇, 李宝江. 乳腺癌新辅助化疗中循环肿瘤细胞的动态变化及疗效观察［J］. 中国肿瘤临床, 2013, 40(23): 1431-1435.

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[4]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[5]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[6]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[7]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[8]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[9]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[10]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[11]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[12]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[13]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[14]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[15]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.